What Happened to Leprosy and Does It Still Exist?

Leprosy, now formally called Hansen’s disease, never disappeared. The World Health Organization still records over 200,000 new cases each year, concentrated heavily in India, Brazil, and Indonesia but appearing on every inhabited continent. What changed is that effective antibiotics, introduced in the mid-twentieth century, turned a disease once considered a death sentence into something curable in months. The bacterium behind it, though, remains stubbornly present in human populations and, as researchers have discovered, in surprising animal hosts. The story of where leprosy went is less about eradication and more about shifting geography, persistent blind spots, and a disease that quietly adapted while the world assumed it had moved on.

A Bacterium That Barely Functions

Leprosy is caused by Mycobacterium leprae, a slow-growing, rod-shaped bacterium first identified by Norwegian physician Gerhard Armauer Hansen in 1873. To this day, no one has managed to grow the organism in a laboratory culture dish. It reproduces inside living cells, dividing roughly once every two weeks, which is extraordinarily slow compared to bacteria that cause common infections. That sluggish pace helps explain why leprosy takes years to show symptoms after a person is exposed.

When scientists sequenced the full genome of M. leprae, they found something unusual: the bacterium had undergone extreme “reductive evolution,” shedding roughly half of its functional genes and replacing them with broken, nonfunctional copies called pseudogenes.¹ Compared to its close relative, the tuberculosis bacterium, M. leprae has a notably smaller genome and has lost the ability to carry out many metabolic processes on its own.² It depends entirely on the cells it infects for survival. That dependence is part of why it can’t be grown in a petri dish and why developing new drugs and vaccines has been so difficult.

How Leprosy Attacks Nerves

M. leprae is the only known human pathogen that specifically targets the Schwann cells surrounding peripheral nerves.³ Schwann cells insulate nerve fibers and help signals travel properly, so when the bacterium invades them, the consequences are devastating. Inside these cells, the organism multiplies without triggering a strong initial immune response, gradually destroying the protective myelin coating around nerves.⁴

The damage isn’t caused solely by the bacterium itself. When the immune system eventually recognizes that Schwann cells are harboring the invader, inflammatory T cells attack and destroy the infected cells, taking healthy nerve tissue with them.⁵ Research in armadillos, one of the few animal models for the disease, has shown that infection triggers sustained Schwann cell overgrowth alongside progressive loss of nerve fibers in the extremities, suggesting the excess proliferation itself contributes to nerve damage.⁶ The result is numbness, muscle weakness, and, over time, the disfiguring injuries that gave leprosy its fearsome historical reputation. People don’t lose fingers or toes because the disease eats them away; they lose them because they can’t feel injuries that go untreated.

Why Your Immune Response Determines What Happens

One of the distinctive features of leprosy is that the same bacterium produces dramatically different disease in different people. The outcome depends almost entirely on how the infected person’s immune system responds. At one end of the spectrum sits tuberculoid leprosy, where a strong cell-mediated immune response keeps the bacteria contained. Patients typically have only a few skin patches and limited nerve involvement. At the other end is lepromatous leprosy, where the immune system fails to control the bacterium and it spreads widely through the skin, nerves, and other tissues.⁷

Complicating things further, patients can experience sudden flare-ups called leprosy reactions. In a type 1 (reversal) reaction, existing skin lesions become inflamed and nerves swell painfully, often leading to rapid loss of sensation and motor function. These reactions are the primary cause of the disabilities still associated with the disease.⁸ A second kind of reaction, called erythema nodosum leprosum, occurs mainly in lepromatous patients and involves immune-complex deposition, neutrophil infiltration, and systemic inflammation that can affect the eyes, joints, and kidneys.⁹ These reactions can strike during treatment or even years after the bacterium has been killed, which is why “cured” patients still need monitoring.

The Rise and Fall in Europe

For most people in wealthy nations, leprosy feels like a medieval problem, and the European timeline reinforces that impression. The disease spread across Europe during Roman times through military campaigns and trade. After a resurgence that peaked around 1350 AD, leprosy gradually declined over several centuries until it effectively vanished from most of the continent.¹⁰ Historians and epidemiologists have debated the reasons for centuries. Improved nutrition and living conditions likely played a role, as did the devastation of the Black Death, which may have killed leprosy patients disproportionately. The rise of tuberculosis, caused by a related mycobacterium, may have conferred some cross-immunity. Quarantine practices, while ethically brutal, also reduced transmission.

But the disappearance was never total. Pockets of leprosy persisted in parts of Norway, Portugal, and southeastern Europe into the twentieth century. And importantly, the decline in Europe said nothing about the rest of the world. In tropical and subtropical regions with poverty, crowding, and limited healthcare, leprosy continued to thrive.

Where Leprosy Is Found Today

India accounts for more than half of the world’s newly detected cases each year, followed by Brazil and Indonesia. A meta-analysis pooling data from 30 studies found that about two-thirds of leprosy patients are male, roughly seven in ten have the multibacillary (more infectious) form, and about one in five already show visible disability at diagnosis.¹¹ That last number is sobering. It means the disease is being caught far too late in a large proportion of cases, after irreversible nerve damage has already occurred. About one in nine cases are in children, a signal that transmission is ongoing rather than burning itself out.

Cases also appear regularly in parts of Africa, the Pacific Islands, and Southeast Asia. Leprosy has not been eliminated in any meaningful biological sense; it has been reduced to numbers that allow wealthy nations to ignore it.

Leprosy in the United States

The U.S. reports roughly 150 to 200 new cases annually, and a growing share of them are in people who have never traveled internationally. Florida in particular has seen a rise in locally acquired infections, leading researchers to describe leprosy as endemic in the southeastern United States.¹²¹³ Cases have appeared in patients with no obvious risk factors other than living in areas where armadillos are common, suggesting that zoonotic transmission from animals is a real and possibly growing pathway.¹⁴

Armadillos, Squirrels, and Other Animal Hosts

For most of its history, leprosy was considered a strictly human disease. That changed when researchers discovered that nine-banded armadillos in the southern United States harbor M. leprae naturally. A study in the Southeast found that about one in six armadillos tested had evidence of infection, and over 40% of human leprosy patients in the region carried a bacterial genotype closely matching strains found in armadillos.¹⁵ The implication is clear: people are catching leprosy from armadillos, whether through direct contact or environmental exposure.¹⁶ Humans and armadillos in the region share a specific M. leprae strain that strongly suggests back-and-forth transmission between the two species.¹⁷

Even more surprising was the discovery that red squirrels in the British Isles carry M. leprae. On Brownsea Island off the English coast, researchers found infected squirrels with leprosy-like lesions, and the bacterial strains sequenced from these animals were most closely related to strains recovered from medieval human skeletons buried in 13th-century England and 14th-century Denmark.¹⁸ The finding suggests that leprosy may have persisted silently in a wildlife reservoir for centuries after it disappeared from the European human population. Ancient genomes have confirmed that medieval Europe hosted a high diversity of M. leprae strains, some of which survive today in armadillos, red squirrels, and human populations across different continents.¹⁹

The existence of animal reservoirs complicates any hope of total eradication. Even if every human case were treated tomorrow, the bacterium would persist in wildlife, with the potential to spill back into human populations.

Treatment and the Road to a Cure

Until the 1940s, there was no effective treatment for leprosy. Chaulmoogra oil, derived from tree seeds, was the standard remedy for centuries, and its effectiveness was marginal at best. The introduction of dapsone in the 1940s was the first real breakthrough, but using it alone led to widespread drug resistance. The modern standard, adopted by the WHO in the 1980s, is multidrug therapy (MDT), a combination of dapsone, rifampicin, and clofazimine. Treatment lasts six months for patients with fewer bacteria and twelve months for those with a higher bacterial load.²⁰ More recently, the WHO has proposed a uniform six-month regimen for all patients, regardless of disease classification, to simplify field-level delivery.

MDT is strikingly effective. Relapse rates after completion are very low, and a patient typically becomes noninfectious within days of starting treatment. The problem is not the drugs; it is getting patients diagnosed before irreversible nerve damage sets in. Diagnostic delay remains the single biggest obstacle to reducing disability worldwide.

The Drug Resistance Question

Because M. leprae cannot be cultured in a lab, testing for drug resistance requires molecular techniques that look for mutations in specific genes. A systematic review found mutation rates of roughly 4% for the gene linked to dapsone resistance, about 4% for rifampicin resistance, and around 1% for fluoroquinolone resistance across global studies.²¹ Those numbers are low compared to many other infectious diseases, but rifampicin is the most powerful drug in the regimen, and even a small amount of resistance to it is concerning.

More reassuring data came from the Comoros Islands, where deep-sequencing of samples from over 250 patients found no resistance mutations in the genes for rifampicin, dapsone, or the main fluoroquinolone target, even among patients whose communities had received prophylactic rifampicin.²² Rapid molecular tests for resistance now exist and can identify mutations directly from patient samples.²³ Surveillance is still patchy, though, and resistance could emerge more rapidly in areas where patients receive incomplete treatment.

Preventing New Cases

There is no dedicated leprosy vaccine, but the BCG vaccine, developed for tuberculosis, provides partial protection because the two bacteria are related. A systematic review of randomized controlled trials found that BCG was the single most effective preventive intervention, roughly halving the risk of developing leprosy compared to placebo.²⁴ In countries where BCG is given routinely at birth, this offers some background protection, though it is far from complete.

A complementary strategy is post-exposure prophylaxis with a single dose of rifampicin (SDR) given to close contacts of newly diagnosed patients. Large-scale programs have shown that SDR can be safely integrated into existing leprosy control efforts and is well accepted by patients, their contacts, and healthcare workers.²⁵ One trial combining BCG vaccination with a follow-up dose of rifampicin found a 42% reduction in the milder form of leprosy among contacts, though the study was too small to reach statistical significance.²⁶ The combination approach is promising, but logistics matter: identifying contacts, tracing them, and delivering prophylaxis in remote settings where leprosy is most common is expensive and labor-intensive.

Better Diagnostics for a Difficult Disease

Leprosy diagnosis still relies heavily on clinical examination: a doctor looks for numb skin patches, thickened nerves, and acid-fast bacteria in skin smears. In many endemic regions, trained examiners are scarce, and the disease mimics other conditions closely enough to be missed. Researchers have been working on point-of-care rapid tests that could be used in the field without laboratory equipment. One approach detects antibodies against PGL-I, a molecule unique to the surface of M. leprae, and a rapid test based on this principle now meets WHO criteria for field deployment.²⁷ Another prototype measures six immune biomarkers simultaneously from a fingerstick blood sample, allowing it to detect both high- and low-bacterial-load forms of the disease.²⁸ These tools could eventually cut the diagnostic delay that allows nerve damage to accumulate before treatment begins.²⁹

The Stigma That Outlasts the Disease

Perhaps the most persistent feature of leprosy is not the bacterium but the social consequences. For centuries, people with the disease were forcibly isolated. In Hawaii, beginning in the 1860s, leprosy patients were banished to the remote Kalaupapa peninsula on Molokai, separated from their families for life in a policy driven as much by racial prejudice against Native Hawaiians and immigrants as by genuine public health concern.³⁰ In Japan, the government maintained a lifetime quarantine policy well into the modern era, continuing to confine patients even after effective antibiotics became available. That policy was not formally ended until 1996, and the government later apologized for the human rights violations it entailed.³¹

The renaming of the disease to “Hansen’s disease” was itself an attempt to break the association between the clinical condition and the loaded biblical-era word “leper.”³² The effort has had mixed success. In many endemic countries, a diagnosis still carries profound social consequences: rejection by family, loss of employment, exclusion from marriage. Fear of stigma drives people to hide symptoms, delaying treatment and worsening the disabilities that feed the cycle of prejudice. Tackling stigma is now officially part of WHO leprosy strategy, but progress is slow when centuries of cultural association are baked into language, literature, and religious texts.

Life After Cure

Being declared “cured” of leprosy means the bacterium is dead, but it does not mean a patient is whole. Nerve damage present at the time of treatment is often permanent, and leprosy reactions can continue for years after the bacteria are gone. Patients may be left with numb hands or feet, muscle weakness, chronic wounds, or visible deformities. Reconstructive surgery can make a substantial difference: studies of patients who underwent corrective procedures found significant improvement in their ability to perform daily activities independently, compared to those who declined surgery.³³ In one assessment, the proportion of patients requiring full assistance for hand tasks dropped from about half to under a fifth after surgery.³⁴

Physical rehabilitation, including splinting, occupational therapy, and training in self-care to protect numb limbs from injury, remains essential for preventing further deterioration.³⁵ In practice, though, many patients in endemic areas have limited access to these services. The global focus on case detection and antibiotic treatment, while important, has sometimes overshadowed the need for long-term rehabilitation of people already living with disability.

Why Eradication Is Unlikely Anytime Soon

The WHO declared leprosy “eliminated as a public health problem” at the global level in 2000, meaning prevalence dropped below one case per ten thousand people. That milestone was real but misleading. It was a statistical threshold, not a biological one. More than 200,000 new cases are still detected every year, and the true number is likely higher because diagnosis depends on patients seeking care and clinicians recognizing a disease many have never seen in person.

Several features of the disease make eradication exceptionally hard. The incubation period averages three to five years and can stretch beyond a decade, so a person may transmit the bacterium long before anyone knows they are infected. Animal reservoirs in armadillos and squirrels mean the pathogen has fallback hosts even if human transmission were somehow interrupted. No diagnostic test reliably identifies people who carry the bacterium but haven’t developed symptoms yet. And funding for leprosy research is a fraction of what goes to diseases considered more prominent, despite the ongoing toll of disability. The disease occupies an awkward place: too rare in wealthy countries to attract pharmaceutical investment, too common in poor ones to be ignored, and too slow-moving to generate the urgency that drives funding for outbreaks. Leprosy persists not because it is unbeatable, but because the world has other priorities.